Sugentech (253840) Stock Overview

Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers Multiplex BLOT disease diagnostic devices, such as immunoblot processor, semi and full automation, and molecular diagnostic systems, as well as test items; and self-testing products, including digital ovulation, pregnancy test, and early sign pregnancy test, as well as mobile testing products. It also provides point of care testing analyzers and test items for testing of M.tuberculosis, M.bovis, SARS-CoV-2 antibodies and antigens, flu A/B antigens, and CRP/hsCRP /dualCRP, as well as for measuring procalcitonin, troponin I, hemoglobinA1c, human chorionic gonadotropin, immunoglobulin E, and influenza A/B. The company was formerly known as Accugen Healthcare, Inc. and changed its name to Sugentech Inc. in October 2013. Sugentech Inc. was founded in 2011 and is headquartered in Daejeon, South Korea.